Publications by authors named "John Gerecitano"

47Publications

Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

Authors:
Connie L Batlevi Fushen Sha Anna Alperovich Ai Ni Katy Smith Zhitao Ying John F Gerecitano Paul A Hamlin Steve M Horwitz Erel Joffe Anita Kumar Matthew J Matasar Alison J Moskowitz Craig H Moskowitz Ariela Noy Colette Owens Lia M Palomba David Straus Gottfried von Keudell Andrew D Zelenetz Venkatraman E Seshan Stefano Luminari Luigi Marcheselli Massimo Federico Anas Younes

Eur J Cancer 2020 02 8;126:78-90. Epub 2020 Jan 8.

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
February 2020

Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

Authors:
Nagavarakishore Pillarsetty Komal Jhaveri Tony Taldone Eloisi Caldas-Lopes Blesida Punzalan Suhasini Joshi Alexander Bolaender Mohammad M Uddin Anna Rodina Pengrong Yan Anson Ku Thomas Ku Smit K Shah Serge Lyashchenko Eva Burnazi Tai Wang Nicolas Lecomte Yelena Janjigian Anas Younes Connie W Batlevi Monica L Guzman Gail J Roboz Jacek Koziorowski Pat Zanzonico Mary L Alpaugh Adriana Corben Shanu Modi Larry Norton Steven M Larson Jason S Lewis Gabriela Chiosis John F Gerecitano Mark P S Dunphy

Cancer Cell 2019 11 24;36(5):559-573.e7. Epub 2019 Oct 24.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article and Find Full Text PDF
November 2019

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:
Sven Borchmann Erel Joffe Craig H Moskowitz Andrew D Zelenetz Ariela Noy Carol S Portlock John F Gerecitano Connie L Batlevi Philip C Caron Pamela Drullinsky Audrey Hamilton Paul A Hamlin Steven M Horwitz Anita Kumar Matthew J Matasar Alison J Moskowitz Colette N Owens M Lia Palomba Anas Younes David J Straus

Blood 2019 05 15;133(20):2121-2129. Epub 2019 Feb 15.

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article and Find Full Text PDF
May 2019

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Authors:
Andrew M Intlekofer Erel Joffe Connie L Batlevi Patrick Hilden Jie He Venkatraman E Seshan Andrew D Zelenetz M Lia Palomba Craig H Moskowitz Carol Portlock David J Straus Ariela Noy Steven M Horwitz John F Gerecitano Alison Moskowitz Paul Hamlin Matthew J Matasar Anita Kumar Marcel R van den Brink Kristina M Knapp Janine D Pichardo Michelle K Nahas Sally E Trabucco Tariq Mughal Amanda R Copeland Elli Papaemmanuil Mathai Moarii Ross L Levine Ahmet Dogan Vincent A Miller Anas Younes

Blood Cancer J 2018 06 12;8(6):60. Epub 2018 Jun 12.

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
June 2018

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:
Matthew S Davids Michael Hallek William Wierda Andrew W Roberts Stephan Stilgenbauer Jeffrey A Jones John F Gerecitano Su Young Kim Jalaja Potluri Todd Busman Andrea Best Maria E Verdugo Elisa Cerri Monali Desai Peter Hillmen John F Seymour

Clin Cancer Res 2018 09 12;24(18):4371-4379. Epub 2018 Jun 12.

Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia.

View Article and Find Full Text PDF
September 2018

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:
John F Seymour Thomas J Kipps Barbara Eichhorst Peter Hillmen James D'Rozario Sarit Assouline Carolyn Owen John Gerecitano Tadeusz Robak Javier De la Serna Ulrich Jaeger Guillaume Cartron Marco Montillo Rod Humerickhouse Elizabeth A Punnoose Yan Li Michelle Boyer Kathryn Humphrey Mehrdad Mobasher Arnon P Kater

N Engl J Med 2018 Mar;378(12):1107-1120

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).

View Article and Find Full Text PDF
March 2018

In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine.

Authors:
Mark P S Dunphy James J Harding Sriram Venneti Hanwen Zhang Eva M Burnazi Jacqueline Bromberg Antonio M Omuro James J Hsieh Ingo K Mellinghoff Kevin Staton Christina Pressl Bradley J Beattie Pat B Zanzonico John F Gerecitano David P Kelsen Wolfgang Weber Serge K Lyashchenko Hank F Kung Jason S Lewis

Radiology 2018 05 31;287(2):667-675. Epub 2018 Jan 31.

From the Department of Radiology (M.P.S.D., W.W., J.S.L.), Department of Medicine (J.J.H., J.B., A.M.O., J.J.H., I.K.M., J.F.G., D.P.K.), Radiochemistry and Molecular Imaging Probe Core (H.Z., E.M.B., S.K.L., J.S.L.), and Department of Medical Physics (B.J.B., P.B.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room S113E, New York, NY 10065; Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY (H.Z., K.S., J.S.L.); Department of Radiology, Weill-Cornell Medical College, New York, NY (M.P.S.D., W.W., J.S.L.); Laboratory of Neural Systems, the Rockefeller University, New York, NY (C.P.); Department of Pathology, University of Michigan, Ann Arbor, Mich (S.V.); and Departments of Radiology and Pharmacology, University of Pennsylvania, Philadelphia, Pa (H.F.K.).

View Article and Find Full Text PDF
May 2018

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

Authors:
Craig S Sauter Matthew J Matasar Heiko Schoder Sean M Devlin Pamela Drullinsky John Gerecitano Anita Kumar Ariela Noy Maria L Palomba Carol S Portlock David J Straus Andrew D Zelenetz Susan J McCall Shoshana T Miller Amanda I Courtien Anas Younes Craig H Moskowitz

Blood 2018 04 31;131(16):1805-1808. Epub 2018 Jan 31.

Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.

View Article and Find Full Text PDF
April 2018

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

Authors:
Anas Younes Gilles Salles Giovanni Martinelli Robert Gregory Bociek Dolores Caballero Barrigon Eva González Barca Mehmet Turgut John Gerecitano Oliver Kong Chaitali Babanrao Pisal Ranjana Tavorath Won Seog Kim

Haematologica 2017 12 29;102(12):2104-2112. Epub 2017 Sep 29.

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

View Article and Find Full Text PDF
December 2017

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Authors:
Alison J Moskowitz Heiko Schöder Somali Gavane Katie L Thoren Martin Fleisher Joachim Yahalom Susan J McCall Briana R Cadzin Stephanie Y Fox John Gerecitano Ravinder Grewal Paul A Hamlin Steven M Horwitz Anita Kumar Matthew Matasar Andy Ni Ariela Noy M Lia Palomba Miguel-Angel Perales Carol S Portlock Craig Sauter David Straus Anas Younes Andrew D Zelenetz Craig H Moskowitz

Blood 2017 11 5;130(20):2196-2203. Epub 2017 Sep 5.

Lymphoma Service and.

View Article and Find Full Text PDF
November 2017

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Authors:
Jacob D Soumerai Andrew D Zelenetz Craig H Moskowitz M Lia Palomba Paul A Hamlin Ariela Noy David J Straus Alison J Moskowitz Anas Younes Matthew J Matasar Steven M Horwitz Carol S Portlock Jason A Konner Mrinal M Gounder David M Hyman Martin H Voss Matthew G Fury Devika Gajria Richard D Carvajal Alan L Ho Jan H Beumer Brian Kiesel Zhigang Zhang Alice Chen Richard F Little Christine Jarjies Thu O Dang Fallon France Nishant Mishra John F Gerecitano

Clin Cancer Res 2017 Aug 17;23(15):4119-4126. Epub 2017 Mar 17.

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article and Find Full Text PDF
August 2017

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Authors:
Lillian M Smyth Kelsey R Monson Komal Jhaveri Alexander Drilon Bob T Li Wassim Abida Gopa Iyer John F Gerecitano Mrinal Gounder James J Harding Martin H Voss Vicky Makker Alan L Ho Pedram Razavi Alexia Iasonos Philip Bialer Mario E Lacouture Jerrold B Teitcher Joseph P Erinjeri Nora Katabi Matthew G Fury David M Hyman

Invest New Drugs 2017 12 9;35(6):742-750. Epub 2017 Mar 9.

Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Avenue, New York, NY, USA.

View Article and Find Full Text PDF
December 2017

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:
Matthew S Davids Andrew W Roberts John F Seymour John M Pagel Brad S Kahl William G Wierda Soham Puvvada Thomas J Kipps Mary Ann Anderson Ahmed Hamed Salem Martin Dunbar Ming Zhu Franklin Peale Jeremy A Ross Lori Gressick Monali Desai Su Young Kim Maria Verdugo Rod A Humerickhouse Gary B Gordon John F Gerecitano

J Clin Oncol 2017 Mar 17;35(8):826-833. Epub 2017 Jan 17.

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

View Article and Find Full Text PDF
March 2017

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

Authors:
Jeffrey R Infante Philippe A Cassier John F Gerecitano Petronella O Witteveen Rashmi Chugh Vincent Ribrag Abhijit Chakraborty Alessandro Matano Jason R Dobson Adam S Crystal Sudha Parasuraman Geoffrey I Shapiro

Clin Cancer Res 2016 Dec 19;22(23):5696-5705. Epub 2016 Aug 19.

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF
December 2016

The epichaperome is an integrated chaperome network that facilitates tumour survival.

Authors:
Anna Rodina Tai Wang Pengrong Yan Erica DaGama Gomes Mark P S Dunphy Nagavarakishore Pillarsetty John Koren John F Gerecitano Tony Taldone Hongliang Zong Eloisi Caldas-Lopes Mary Alpaugh Adriana Corben Matthew Riolo Brad Beattie Christina Pressl Radu I Peter Chao Xu Robert Trondl Hardik J Patel Fumiko Shimizu Alexander Bolaender Chenghua Yang Palak Panchal Mohammad F Farooq Sarah Kishinevsky Shanu Modi Oscar Lin Feixia Chu Sujata Patil Hediye Erdjument-Bromage Pat Zanzonico Clifford Hudis Lorenz Studer Gail J Roboz Ethel Cesarman Leandro Cerchietti Ross Levine Ari Melnick Steven M Larson Jason S Lewis Monica L Guzman Gabriela Chiosis

Nature 2016 Oct 5;538(7625):397-401. Epub 2016 Oct 5.

Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA.

View Article and Find Full Text PDF
October 2016

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.

Authors:
Ying Chen Sandra Catalina Camacho Thomas R Silvers Albiruni R A Razak Nashat Y Gabrail John F Gerecitano Eva Kalir Elena Pereira Brad R Evans Susan J Ramus Fei Huang Nolan Priedigkeit Estefania Rodriguez Michael Donovan Faisal Khan Tamara Kalir Robert Sebra Andrew Uzilov Rong Chen Rileen Sinha Richard Halpert Jean-Noel Billaud Sharon Shacham Dilara McCauley Yosef Landesman Tami Rashal Michael Kauffman Mansoor R Mirza Morten Mau-Sørensen Peter Dottino John A Martignetti

Clin Cancer Res 2017 Mar 20;23(6):1552-1563. Epub 2016 Sep 20.

Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article and Find Full Text PDF
March 2017

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Authors:
Anita Kumar Carla Casulo Joachim Yahalom Heiko Schöder Paul M Barr Philip Caron April Chiu Louis S Constine Pamela Drullinsky Jonathan W Friedberg John F Gerecitano Audrey Hamilton Paul A Hamlin Steven M Horwitz Alexandra G Jacob Matthew J Matasar Gianna N McArthur Susan J McCall Alison J Moskowitz Ariela Noy Maria L Palomba Carol S Portlock David J Straus Nicholas VanderEls Stephanie L Verwys Joanna Yang Anas Younes Andrew D Zelenetz Zhigang Zhang Craig H Moskowitz

Blood 2016 09 25;128(11):1458-64. Epub 2016 Jul 25.

Memorial Sloan Kettering Cancer Center, New York, NY; and.

View Article and Find Full Text PDF
September 2016

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

Authors:
Anas Younes Jesus G Berdeja Manish R Patel Ian Flinn John F Gerecitano Sattva S Neelapu Kevin R Kelly Amanda R Copeland Amy Akins Myles S Clancy Lucy Gong Jing Wang Anna Ma Jaye L Viner Yasuhiro Oki

Lancet Oncol 2016 05 31;17(5):622-31. Epub 2016 Mar 31.

Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
May 2016

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Authors:
Albiruni R Abdul Razak Morten Mau-Soerensen Nashat Y Gabrail John F Gerecitano Anthony F Shields Thaddeus J Unger Jean R Saint-Martin Robert Carlson Yosef Landesman Dilara McCauley Tami Rashal Ulrik Lassen Richard Kim Lee-Anne Stayner Mansoor R Mirza Michael Kauffman Sharon Shacham Amit Mahipal

J Clin Oncol 2016 12 31;34(34):4142-4150. Epub 2016 Oct 31.

Albiruni R. Abdul Razak and Lee-Anne Stayner, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Morten Mau-Soerensen and Ulrik Lassen, Rigshospitalet, Copenhagen, Denmark; Nashat Y. Gabrail, Gabrail Cancer Institute, Canton, OH; John F. Gerecitano, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY; Anthony F. Shields, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Thaddeus J. Unger, Jean R. Saint-Martin, Robert Carlson, Yosef Landesman, Dilara McCauley, Tami Rashal, Mansoor R. Mirza, Michael Kauffman, and Sharon Shacham, Karyopharm Therapeutics, Newton, MA; and Richard Kim and Amit Mahipal, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article and Find Full Text PDF
December 2016

A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.

Authors:
Carol S Portlock Paul A Hamlin John F Gerecitano Ariela Noy Maria Lia Palomba Janelle Walkley Stacie Corcoran Jocelyn Migliacci Heiko Schoder Genovefa Papanicolaou Arnold J Markowitz

Tumor Microenviron Ther 2015 Feb 18;2(1):14-18. Epub 2015 Feb 18.

Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA.

View Article and Find Full Text PDF
February 2015

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:
Andrew W Roberts Matthew S Davids John M Pagel Brad S Kahl Soham D Puvvada John F Gerecitano Thomas J Kipps Mary Ann Anderson Jennifer R Brown Lori Gressick Shekman Wong Martin Dunbar Ming Zhu Monali B Desai Elisa Cerri Sari Heitner Enschede Rod A Humerickhouse William G Wierda John F Seymour

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article and Find Full Text PDF
January 2016

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Authors:
Rebecca L Goldstein Shao Ning Yang Tony Taldone Betty Chang John Gerecitano Kojo Elenitoba-Johnson Rita Shaknovich Wayne Tam John P Leonard Gabriela Chiosis Leandro Cerchietti Ari Melnick

J Clin Invest 2015 Nov 3;125(12):4559-71. Epub 2015 Nov 3.

View Article and Find Full Text PDF
November 2015

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:
Wyndham H Wilson Ryan M Young Roland Schmitz Yandan Yang Stefania Pittaluga George Wright Chih-Jian Lih P Mickey Williams Arthur L Shaffer John Gerecitano Sven de Vos Andre Goy Vaishalee P Kenkre Paul M Barr Kristie A Blum Andrei Shustov Ranjana Advani Nathan H Fowler Julie M Vose Rebecca L Elstrom Thomas M Habermann Jacqueline C Barrientos Jesse McGreivy Maria Fardis Betty Y Chang Fong Clow Brian Munneke Davina Moussa Darrin M Beaupre Louis M Staudt

Nat Med 2015 Aug 20;21(8):922-6. Epub 2015 Jul 20.

Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.

View Article and Find Full Text PDF
August 2015

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Authors:
Alison J Moskowitz Heiko Schöder Joachim Yahalom Susan J McCall Stephanie Y Fox John Gerecitano Ravinder Grewal Paul A Hamlin Steven Horwitz Rachel Kobos Anita Kumar Matthew Matasar Ariela Noy M Lia Palomba Miguel-Angel Perales Carol S Portlock Craig Sauter Neerav Shukla Peter Steinherz David Straus Tanya Trippett Anas Younes Andrew Zelenetz Craig H Moskowitz

Lancet Oncol 2015 Mar 13;16(3):284-92. Epub 2015 Feb 13.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
March 2015

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

Authors:
David M Hyman Alexandra E Snyder Richard D Carvajal John F Gerecitano Martin H Voss Alan L Ho Jason Konner Jennifer L Winkelmann Megan A Stasi Kelsey R Monson Alexia Iasonos David R Spriggs Philip Bialer Mario E Lacouture Jerrold B Teitcher Nora Katabi Matthew G Fury

Cancer Chemother Pharmacol 2015 Apr 12;75(4):747-55. Epub 2015 Feb 12.

Developmental Therapeutics Clinic, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Avenue, New York, NY, USA.

View Article and Find Full Text PDF
April 2015

The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study.

Authors:
Owen A O'Connor John Gerecitano Henrik Van Deventer John Hainsworth Kelly M Zullo Khalil Saikali Joseph Seroogy Andrew Wolff Rafael Escandón

Leuk Lymphoma 2015 11;56(9):2585-91. Epub 2015 Sep 11.

e Cytokinetics, Inc. , South San Francisco , CA , USA.

View Article and Find Full Text PDF
August 2016

Ex vivo treatment response of primary tumors and/or associated metastases for preclinical and clinical development of therapeutics.

Authors:
Adriana D Corben Mohammad M Uddin Brooke Crawford Mohammad Farooq Shanu Modi John Gerecitano Gabriela Chiosis Mary L Alpaugh

J Vis Exp 2014 Oct 2(92):e52157. Epub 2014 Oct 2.

Department of Surgery, Memorial Sloan Kettering Cancer Center;

View Article and Find Full Text PDF
October 2014

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.

Authors:
David J Straus Paul A Hamlin Matthew J Matasar Maria Lia Palomba Pamela R Drullinsky Andrew D Zelenetz John F Gerecitano Ariela Noy Audrey M Hamilton Rebecca Elstrom Brett Wegner Katy Wortman David Cella

Br J Haematol 2015 Mar 15;168(5):663-70. Epub 2014 Oct 15.

Memorial Sloan-Kettering Cancer Center, Division of Hematologic Oncology, Lymphoma Service, New York, NY, USA.

View Article and Find Full Text PDF
March 2015

SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.

Authors:
John Gerecitano

J Hematol Oncol 2014 Oct 4;7:67. Epub 2014 Oct 4.

View Article and Find Full Text PDF
October 2014

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Authors:
Komal Jhaveri Stefan O Ochiana Mark Ps Dunphy John F Gerecitano Adriana D Corben Radu I Peter Yelena Y Janjigian Erica M Gomes-DaGama John Koren Shanu Modi Gabriela Chiosis

Expert Opin Investig Drugs 2014 May 26;23(5):611-28. Epub 2014 Mar 26.

New York University Cancer Institute, NYU Clinical Cancer Center, Division of Hematology/Medical Oncology , NY , USA.

View Article and Find Full Text PDF
May 2014

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Authors:
Michelle A Rudek Page C Moore Ronald T Mitsuyasu Bruce J Dezube David Aboulafia John Gerecitano Ryan Sullivan Mary E Cianfrocca David H Henry Lee Ratner Missak Haigentz Afshin Dowlati Richard F Little Susan Percy Ivy John F Deeken

Cancer 2014 Apr 28;120(8):1194-202. Epub 2014 Jan 28.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.

View Article and Find Full Text PDF
April 2014

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Authors:
Alison J Moskowitz Paul A Hamlin Miguel-Angel Perales John Gerecitano Steven M Horwitz Matthew J Matasar Ariela Noy Maria Lia Palomba Carol S Portlock David J Straus Tricia Graustein Andrew D Zelenetz Craig H Moskowitz

J Clin Oncol 2013 Feb 17;31(4):456-60. Epub 2012 Dec 17.

Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.

View Article and Find Full Text PDF
February 2013

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.

Authors:
Alexia Iasonos Mrinal Gounder David R Spriggs John F Gerecitano David M Hyman Sarah Zohar John O'Quigley

Clin Cancer Res 2012 Oct 23;18(19):5179-87. Epub 2012 Jul 23.

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
October 2012

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.

Authors:
John F Gerecitano Joe J Stephenson Nancy L Lewis Anna Osmukhina Jianguo Li Kaida Wu Zhiping You Dennis Huszar Jeffrey M Skolnik Gary K Schwartz

Invest New Drugs 2013 Apr 22;31(2):355-62. Epub 2012 May 22.

Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article and Find Full Text PDF
April 2013

Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.

Authors:
John Gerecitano Sivaraman Gounder Julie Teruya-Feldstein Maria Arcila Shahiba Ogilvie Camille Gonzalez Dorothy Lin Junting Zheng Zhigang Zhang Alice McDonald George Mulligan Owen A O'Connor

Br J Haematol 2012 Jul 26;158(2):290-292. Epub 2012 Apr 26.

NYU Langone Medical Center, NYU Cancer Institute, New York, NY, USA.

View Article and Find Full Text PDF
July 2012

Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study.

Authors:
Angelo E Volandes Tomer T Levin Susan Slovin Richard D Carvajal Eileen M O'Reilly Mary Louise Keohan Maria Theodoulou Maura Dickler John F Gerecitano Michael Morris Andrew S Epstein Anastazia Naka-Blackstone Elizabeth S Walker-Corkery Yuchiao Chang Ariela Noy

Cancer 2012 Sep 17;118(17):4331-8. Epub 2012 Jan 17.

General Medicine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

View Article and Find Full Text PDF
September 2012

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

Authors:
Craig H Moskowitz Matt J Matasar Andrew D Zelenetz Stephen D Nimer John Gerecitano Paul Hamlin Steven Horwitz Alison J Moskowitz Ariela Noy Lia Palomba Miguel-Angel Perales Carol Portlock David Straus Jocelyn C Maragulia Heiko Schoder Joachim Yahalom

Blood 2012 Feb 19;119(7):1665-70. Epub 2011 Dec 19.

Lymphoma Disease Management Team, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article and Find Full Text PDF
February 2012

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.

Authors:
John Gerecitano Carol Portlock Paul Hamlin Craig H Moskowitz Ariela Noy David Straus Philip Schulman Otilia Dumitrescu Debra Sarasohn Jennifer Pappanicholaou Alexia Iasonos Zhigang Zhang Qianxing Mo Endri Horanlli Celeste N Rojas Andrew D Zelenetz Owen A O'Connor

Clin Cancer Res 2011 Apr 23;17(8):2493-501. Epub 2011 Feb 23.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10065, USA.

View Article and Find Full Text PDF
April 2011

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Authors:
Wyndham H Wilson Owen A O'Connor Myron S Czuczman Ann S LaCasce John F Gerecitano John P Leonard Anil Tulpule Kieron Dunleavy Hao Xiong Yi-Lin Chiu Yue Cui Todd Busman Steven W Elmore Saul H Rosenberg Andrew P Krivoshik Sari H Enschede Rod A Humerickhouse

Lancet Oncol 2010 Dec 18;11(12):1149-59. Epub 2010 Nov 18.

National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article and Find Full Text PDF
December 2010

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

Authors:
Owen A O'Connor Carol Portlock Craig Moskowitz Paul Hamlin David Straus John Gerecitano Mithat Gonen Otilia Dumitrescu Debra Sarasohn John Butos Ellen Neylon Barbara Mac-Gregor Cortelli Susan Blumel Andrew M Evens Andrew D Zelenetz John Wright Brenda Cooper Jane Winter Julie Vose

Clin Cancer Res 2010 Jan 12;16(2):719-26. Epub 2010 Jan 12.

NYU Cancer Institute, NYU Langone Medical Center, New York, New York, USA.

View Article and Find Full Text PDF
January 2010

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Authors:
Owen A O'Connor A Keith Stewart Marcy Vallone Christopher J Molineaux Lori A Kunkel John F Gerecitano Robert Z Orlowski

Clin Cancer Res 2009 Nov 10;15(22):7085-91. Epub 2009 Nov 10.

NYU Cancer Institute, NYU Langone Medical Center, 522 First Ave., Smilow 1101, New York, NY, USA.

View Article and Find Full Text PDF
November 2009

The future of small molecule inhibitors in lymphoma.

Authors:
John Gerecitano

Curr Oncol Rep 2009 Sep;11(5):378-85

Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article and Find Full Text PDF
September 2009

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.

Authors:
John Gerecitano Carol Portlock Craig Moskowitz Paul Hamlin David Straus Andrew D Zelenetz Zhigang Zhang Otilia Dumitrescu Debra Sarasohn Dorothy Lin Jennifer Pappanicholaou Barbara M Cortelli Ellen Neylon Rachel Hamelers John Wright Owen A O'Connor

Br J Haematol 2009 Sep 16;146(6):652-5. Epub 2009 Jul 16.

Department of Medicine, Memorial Sloan Kettering Cancer Center, Columbia University, New York, NY 10021, USA.

View Article and Find Full Text PDF
September 2009

Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

Authors:
John Gerecitano Andre Goy John Wright Barbara MacGregor-Cortelli Ellen Neylon Mithat Gonen Dixie Esseltine Anthony Boral David Schenkein Klaus Busam Julie Teruya-Feldstein Dana Sachs Owen A O'Connor

Br J Haematol 2006 Aug;134(4):391-8

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article and Find Full Text PDF
August 2006

Novel small molecules in the treatment of lymphomas.

Authors:
John Gerecitano Owen A O'Connor

Cancer Treat Res 2006 ;131:413-60

Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, New York, NY, USA.

View Article and Find Full Text PDF
June 2006

Treatment of Burkitt lymphoma in adults.

Authors:
John Gerecitano David J Straus

Expert Rev Anticancer Ther 2006 Mar;6(3):373-81

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. gerecitj@

View Article and Find Full Text PDF
March 2006

Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.

Authors:
John Gerecitano Clarissa Mathias Rosemarie Mick Kathleen M Duffy Selina Luger Edward A Stadtmauer Stephen J Schuster Donald Tsai Sunita Nasta Jesse Berlin Deborah K Phillips Katherine A High David L Porter

J Hematother Stem Cell Res 2003 Apr;12(2):215-23

Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

View Article and Find Full Text PDF
April 2003